The SVP and General Counsel of Foundation Medicine (NASDAQ: FMI) is Selling SharesBy Carrie Williams
Following Robert Hesslein’s last FMI Sell transaction on January 05, 2017, the stock climbed by 14.2%. In addition to Robert Hesslein, 3 other FMI executives reported Sell trades in the last month.
Based on Foundation Medicine’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $28.82 million and GAAP net loss of $35.61 million. In comparison, last year the company earned revenue of $26.05 million and had a GAAP net loss of $19.02 million. The company has a one year high of $35.30 and a one year low of $15.10. Currently, Foundation Medicine has an average volume of 168.1K.
The insider sentiment on Foundation Medicine has been negative according to 46 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Foundation Medicine, Inc. engages in the provision of information on clinical treatment decisions for patients with cancer. Its clinical molecular information products include FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers. The company was founded by Alexis Borisy, Eric Lander, Todd Golub, Levi Garraway and Matthew Meyerson in November 2009 and is headquartered in Cambridge, MA.